Kim HS, Lee JY, Jung JW, Lee KH, Kim MJ, Park SB. Is mannitol combined with furosemide a new treatment for refractory lymphedema? A case report. World J Clin Cases 2021; 9(29): 8804-8811 [PMID: 34734059 DOI: 10.12998/wjcc.v9.i29.8804]
Corresponding Author of This Article
Si-Bog Park, MD, PhD, Professor, Department of Rehabilitation Medicine, Hanyang University Hospital, 222-1, Wangsimni-ro, Seongdong-gu, Seoul 04763, South Korea. sibopark@hanyang.ac.kr
Research Domain of This Article
Rehabilitation
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 16, 2021; 9(29): 8804-8811 Published online Oct 16, 2021. doi: 10.12998/wjcc.v9.i29.8804
Is mannitol combined with furosemide a new treatment for refractory lymphedema? A case report
Hyeon Seong Kim, Jae Young Lee, Ji Won Jung, Kyu Hoon Lee, Mi Jung Kim, Si-Bog Park
Hyeon Seong Kim, Jae Young Lee, Ji Won Jung, Kyu Hoon Lee, Mi Jung Kim, Si-Bog Park, Department of Rehabilitation Medicine, Hanyang University Hospital, Seoul 04763, South Korea
Author contributions: Kim HS was the patient’s physiatrist, reviewed the literature and contributed to manuscript drafting; Lee JY, Jung JW, Lee KH, and Kim MJ reviewed the literature and contributed to manuscript drafting; Park SB was responsible for manuscript revision for important intellectual content; all authors issued final approval for the version to be submitted.
Informed consent statement: Due to the patient’s stuporous mental status, informed consent was obtained from the patient’s son for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Si-Bog Park, MD, PhD, Professor, Department of Rehabilitation Medicine, Hanyang University Hospital, 222-1, Wangsimni-ro, Seongdong-gu, Seoul 04763, South Korea. sibopark@hanyang.ac.kr
Received: December 19, 2020 Peer-review started: December 19, 2020 First decision: July 18, 2021 Revised: July 30, 2021 Accepted: September 8, 2021 Article in press: September 8, 2021 Published online: October 16, 2021
Core Tip
Core Tip: Mannitol is a hyperosmolar agent and the combination of mannitol and furosemide is a widely used treatment for intracranial pressure control. We found dramatic improvement of refractory lymphedema after administration of mannitol and furosemide. After the mannitol and furosemide were discontinued, the lymphedema worsened in spite of complete decongestive therapy (CDT) and intermittent pneumatic compression (IPC). To identify the presumed effect of mannitol and furosemide on lymphedema, these agents were resumed, and the lymphedema improved again. The present case suggests that the combination of mannitol and furosemide could be considered as another effective therapeutic option for refractory lymphedema when CDT and IPC are ineffective.
